9 results
Objectives:Primary:- To evaluate efficacy as measured by overall survival (OS), with a goal of demonstrating the superiority of inotuzumab ozogamicin when administered in combination with rituximab, compared with an active comparator arm.Secondary…
Image guided surgery in sinonasal inverted papilloma by targeting vascular endothelial growth factor
The main objective is to study if the conjugate bevacizumab-IRDye800CW accumulates more in sinonasal inverted papilloma than in normal sinonasal mucosa, with a TBR of *2 as cutoff value.
The objective of the study is to investigate the feasibility and efficacy of treatment with lenalidomide and rituximab with or without bendamustine in patients with relapsed follicular lymphoma.
Stage 1 Primary ObjectiveTo evaluate the safety and tolerability, determine the expansion dose, and characterize dose-limiting toxicities (DLTs) of escalating doses of furmonertinib administered daily to patients with locally advanced or metastatic…
Primary objectives -To determine whether real-time tumor visualization using targeted fluorescent imaging during breast conserving therapy in breast cancer patients can be achieved intraoperatively and results in adequate assessment of the tumor…
Primary ObjectiveThe primary objective of this study is to evaluate whether the addition of ibrutinib to bendamustine and rituximab will result in prolongation of PFS in subjects with newly diagnosed MCL who are 65 years of age or older.Secondary…
The main objective of this study is to define the optimal dose of fluorescent tracer for intraoperative detection of tumor delineation during breast cancer surgery.
Primary Objectives- Determine the MTD of pixantrone, rituximab (only in CD20 positive tumors), etoposide, and bendamustine in *fit' patients with rel aNHL of B- or T-cell phenotype.- Evaluate the ORR and PFS using the combination of pixantrone…
Primary ObjectiveTo assess the efficacy of furmonertinib compared to platinum-based chemotherapy using progression-free survival (PFS) in previously untreated patients with locally advanced or metastatic non-squamous NSCLC with EGFR exon 20…